Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 01, 2012 (Vol. 32, No. 3)

De-Risking Clinical Development

Best Bet May Be to Repurpose a Well-Defined Drug with Proven Safety and Utility in Humans

  • Taking a drug from the laboratory and preclinical testing arena into first-in-human studies and clinical trials represents the largest, most costly gamble in the drug discovery pipeline. During this phase of development patient safety takes center stage and acquires quantifiable parameters, dosing may require some guesswork and trial-and-error, ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.